36 Healthcare Stocks Moving In Thursday's Pre-Market Session

Gainers

  • Helius Medical Tech, Inc. HSDT stock increased by 88.1% to $0.79 during Thursday's pre-market session. The market cap stands at $15.6 million.
  • Paratek Pharmaceuticals, Inc. PRTK shares moved upwards by 41.7% to $4.18. The market cap stands at $102.6 million.
  • Catalyst Biosciences, Inc. CBIO shares surged 27.9% to $6.10. The market cap seems to be at $65.5 million.
  • Rite Aid, Inc. RAD stock surged 26.9% to $10.60. The market cap stands at $504.8 million.
  • Bionano Genomics, Inc. BNGO shares increased by 10.8% to $1.13. The market cap stands at $20.9 million.
  • Selecta Biosciences, Inc. SELB shares increased by 8.9% to $1.59. The market value of their outstanding shares is at $70.8 million.
  • Bellerophon Therapeutics, Inc. BLPH shares rose 8.7% to $0.36. The market cap seems to be at $31.0 million.
  • Inovio Pharmaceuticals, Inc. INO stock increased by 8.0% to $2.84. The market cap stands at $210.9 million. The most recent rating by Roth Capital, on December 19, is at Buy, with a price target of $13.00.
  • Axsome Therapeutics, Inc. AXSM stock moved upwards by 8.0% to $96.70. The market cap stands at $1.3 billion. The most recent rating by Cantor Fitzgerald, on December 16, is at Overweight, with a price target of $104.00.
  • Sunesis Pharmaceuticals, Inc. SNSS stock increased by 6.5% to $0.31. The market cap stands at $64.8 million.
  • ObsEva, Inc. OBSV shares increased by 6.4% to $3.16. The market cap seems to be at $337.6 million. The most recent rating by H.C. Wainwright, on December 19, is at Buy, with a price target of $40.00.
  • TherapeuticsMD, Inc. TXMD shares surged 5.4% to $2.44. The market cap seems to be at $721.1 million.
  • Karuna Therapeutics, Inc. KRTX stock increased by 4.9% to $69.25. The market cap stands at $1.6 billion. The most recent rating by Stifel Nicolaus, on December 19, is at Buy, with a price target of $126.00.
  • Genfit, Inc. GNFT shares increased by 4.9% to $17.61. The market value of their outstanding shares is at $552.9 million.
  • Moleculin Biotech, Inc. MBRX stock rose 3.8% to $0.99. The market value of their outstanding shares is at $48.9 million. The most recent rating by Oppenheimer, on October 17, is at Outperform, with a price target of $2.00.
  • Seattle Genetics, Inc. SGEN stock rose 3.8% to $117.04. The market cap seems to be at $18.4 billion. The most recent rating by Oppenheimer, on December 12, is at Outperform, with a price target of $124.00.
  • Fortress Biotech, Inc. FBIO stock rose 3.7% to $2.25. The market cap stands at $99.1 million. The most recent rating by B. Riley, on December 18, is at Buy, with a price target of $9.00.
  • Macrogenics, Inc. MGNX stock increased by 3.5% to $10.95. The market cap seems to be at $463.2 million. The most recent rating by Cantor Fitzgerald, on December 19, is at Overweight, with a price target of $17.00.
  • Biocept, Inc. BIOC shares rose 2.9% to $0.24. The market cap seems to be at $16.4 million.
  • Xenetic Biosciences, Inc. XBIO shares increased by 2.6% to $1.59. The market cap stands at $6.8 million.
  • Adamas Pharmaceuticals, Inc. ADMS stock moved upwards by 2.5% to $3.76. The market value of their outstanding shares is at $114.4 million. The most recent rating by Cantor Fitzgerald, on December 17, is at Neutral, with a price target of $7.00.
  • Epizyme, Inc. EPZM stock moved upwards by 2.0% to $20.50. The market cap stands at $1.0 billion. The most recent rating by Morgan Stanley, on December 06, is at Overweight, with a price target of $22.00.
  • Outlook Therapeutics, Inc. OTLK shares moved upwards by 1.7% to $1.17. The market cap seems to be at $46.0 million.
  • Mirum Pharmaceuticals, Inc. MIRM shares moved upwards by 1.6% to $24.15. The market value of their outstanding shares is at $165.0 million.
  • Abeona Therapeutics, Inc. ABEO stock surged 1.5% to $4.00. The market value of their outstanding shares is at $120.9 million.

 

Losers

  • Ekso Bionics Holdings, Inc. EKSO shares decreased by 25.9% to $0.40 during Thursday's pre-market session. The market value of their outstanding shares is at $43.0 million. The most recent rating by H.C. Wainwright, on October 28, is at Buy, with a price target of $1.20.
  • Minerva Neurosciences, Inc. NERV stock plummeted 18.3% to $5.63. The market value of their outstanding shares is at $184.9 million. The most recent rating by H.C. Wainwright, on December 19, is at Buy, with a price target of $20.00.
  • Zafgen, Inc. ZFGN stock fell 5.3% to $0.68. The market cap seems to be at $27.6 million.
  • Amarin Corp, Inc. AMRN shares decreased by 2.5% to $20.30. The market cap stands at $5.8 billion. The most recent rating by Stifel, on December 16, is at Hold, with a price target of $26.00.
  • Ocugen, Inc. OCGN shares declined 2.3% to $0.38. The market value of their outstanding shares is at $19.7 million. The most recent rating by Chardan Capital, on November 27, is at Buy, with a price target of $2.00.
  • Exicure, Inc. XCUR shares plummeted 2.0% to $2.90. The market value of their outstanding shares is at $256.8 million. The most recent rating by Guggenheim, on November 20, is at Buy, with a price target of $9.00.
  • Diffusion Pharmaceuticals, Inc. DFFN stock fell 1.8% to $0.39. The market cap stands at $3.9 million. The most recent rating by H.C. Wainwright, on December 18, is at Buy, with a price target of $3.50.
  • Solid Biosciences, Inc. SLDB shares plummeted 1.6% to $3.90. The market cap seems to be at $508.2 million. The most recent rating by Nomura, on December 18, is at Buy, with a price target of $10.00.
  • Obalon Therapeutics, Inc. OBLN stock plummeted 1.6% to $1.88. The market cap stands at $12.9 million.
  • Sesen Bio, Inc. SESN shares plummeted 1.4% to $0.91. The market value of their outstanding shares is at $123.5 million.
  • Sanofi, Inc. SNY shares decreased by 1.1% to $49.79. The market cap stands at $115.4 billion. According to the most recent rating by Barclays, on December 06, the current rating is at Underweight.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!